Behavioural Influence of Atorvastatin alone and in Combination with Antiepileptics against Electroconvulsions in Mice
DOI:
https://doi.org/10.18034/mjmbr.v4i1.426Keywords:
Atorvastatin, Phenytoin, MES Convulsion, lacosamide, levetiracetam, BehaviorAbstract
The aim of the present study was to investigate the behavioral influence of atorvastatin alone and in combination with antiepileptics like lacosamide and levetiracetam in the mouse after the experimental convulsions induced by maximal electroshock method. The maximal seizure pattern was induced in mice in alternative days for upto 9 days by giving an alternating current of 45 mA for 0.2 Sec. Atorvastatin (10mg/ kg i.p) were administered intraperitoneally 30 min before the electrical induction of seizures in alone and in combination with lacosamide (10mg/kg i.p) and levetiracetam (10mg/kg i.p). Rota rod, hole board, tail suspension and were used to record behavioral effects periodically. Additionally, the effects of administration of atorvastatin on the adverse effect potential of an lacosamide and levetiracetam were assessed in the chimney test for its motor performance. The results shows that, there is a gradual significant increase of muscle grip strength (p<0.05) and reduction in immobility time (p<0.05) on the 7th day which indicates modulatory effect of atorvastatin on behavior while combining with levetiracetam and lacosamide. In hole board test there was a significant increase in head poking were observed which indicates that the given drug atorvastatin has alleviated the anxiety and depression which confirms its modulatory effects on behavior while combining with levetiracetam and lacosamide. In addition to this atorvastatin in combinations with both antiepileptic drugs had no impact on their adverse effects in the chimney test. Based on the study, the results suggest that the HMG-CoA inhibitor atorvastatin fails to protect the seizures alone and in combination with levetiracetam and shows modulatory effects on behavior while combining with antiepileptics in MES convulsion model.
Metrics
Downloads
References
Bersot T.P., Drug therapy for hypercholesterolemia and dyslipidemia. Brunton L, Chabner B, Knollman B editors. Goodman & Gillman’s the pharmacological basis of therapeutics, 12thed. New York: McGraw Hill; 2011. p.893.
Davignon, J., Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004, 109, Suppl III, 39–43. DOI: https://doi.org/10.1161/01.CIR.0000131517.20177.5a
Floris, S., Blezer, E.L., Schreibelt, G., Dopp, E., van der Pol, S.M., Schadee-Eestermans, I.L., Nicolay K. Bloodbrain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain, 2004, 127, 616–627. DOI: https://doi.org/10.1093/brain/awh068
Giros, B., Jaber, M., Jones, S.R., Wightman,R.M., Caron, M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.Nature 1996,379, 606–612. DOI: https://doi.org/10.1038/379606a0
Harvey, B.H, Oosthuizen. F., Brand, L., Wegener, G., Stein, D.J. Stress–restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology.2004, 175, 494–502.
Kulkarni,S.K. Handbook of experimental pharmacology 3rd edition Page No:117,119,135
Laufs, U. Beyond lipid-lowering: effects of statin on endothelial nitric oxide. Eur J Pharmacol. 2003, 58, 719–731.
Losher, W., Schmidt, D.Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. J epilepsy Res.1988; 2:145-181. DOI: https://doi.org/10.1016/0920-1211(88)90054-X
Mandhane, S.N., Aavula, K., Rajamannar, T. Timed pentylenetetrazole infusion test: A compamiceive analysis with s.c. PTZ and MES models of anticonvulsant screening in mice. Seizure. 2007, 16:636-44.
Mandhane, S.N., Aavula, K., Rajamannar, T. Timed pentylenetetrazole infusion test: A compamiceive analysis with s.c. PTZ and MES models of anticonvulsant screening in mice. Seizure. 2007, 16:636-44. DOI: https://doi.org/10.1016/j.seizure.2007.05.005
Perez, G.R.M., Perez, I.J.A., Garcia, D., Sossa, M.H. Neuropharmacological activity of Solanum nigrum fruit. J. Ethnopharmacol.1998, 62:43-48. DOI: https://doi.org/10.1016/S0378-8741(98)00059-2
Ramirez, C., Tercero, I., Pineda, A., Burgos, J.S. Simvastatin is the statin that most efficiently protects against kinate-induced excitotoxicity and memory impairment. J.Alzheimers Dis 2011, 24(1):161-74. DOI: https://doi.org/10.3233/JAD-2010-101653
Ranje, C., Ungerstedt, U. High correlations between number of dopamine cells, dopamine levels and motor performance. Brain Res. 1977,134, 83–93.
Shafaroodi, H., Mezi, L., Fakhrzad, A., Hassanipou, M., Rezayat, M., Dehpour, A.R. The involvement of nitric oxide in the anti-seizure effect of acute Atorvastatin treatment in mice. Neurol Res. 2012; 34(9): 847-53. DOI: https://doi.org/10.1179/1743132812Y.0000000080
Steru, L., Chermat, R., Thierry, B., Simon, P. The tail suspension test: a new method for a new method for screening antidepressants in mice. Psychopharmacology.1985, 85: 367. DOI: https://doi.org/10.1007/BF00428203
Swiader, M. Influence of vigabatrin, a novel antiepileptic drug on the anticonvulsant activity of conventional antiepileptic in pentetetrazole induced seizures in mice. Pol J Pharmacol 2003, 55: 363-370.
Swinyard, E.A. Comparative assay of antiepileptic drugs in mice and rats. J Pharmacol. Exp. Ther. 1952, 106: 319-330.
Taiwe,G.S., Ngo Bum,T..Dimo. Antidepressant, myorelaxant and Anti-anxiety like effects nauclea latifolia smith (Rubiaceae) roots extract in murine models. International journal of pharmacology.2010; 6(4): 364-371 DOI: https://doi.org/10.3923/ijp.2010.364.371
Uhl, G.R., Hall, F.S., Sora, I.Cocaine, reward,movement and monoamine transporters. Mol. Psychiatry. 2002, 7, 21–26.
Uhl, G. R.. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and Parkinsonism. Mov. Disord.2003, 18, S71–S80.
Vaughan, C.J., Delanty, N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999, 30, 1969–1973. Wahner, A.D., Bronstein, J.M., Bordelon, Y.M, Ritz, B. Statin use and the risk of Parkinson disease. Neurology. 2008, 70, 1418–1422.
-- 0 --
